Mazindol controlled release- NLS Pharma

Drug Profile

Mazindol controlled release- NLS Pharma

Alternative Names: NLS 1001; NLS-1

Latest Information Update: 30 Aug 2016

Price : $50

At a glance

  • Originator NLS Pharma
  • Class Anorectics; Small molecules
  • Mechanism of Action Adrenergic receptor agonists; Adrenergic uptake inhibitors; Central nervous system stimulants; Dopamine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Narcolepsy
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Attention-deficit hyperactivity disorder; Narcolepsy

Most Recent Events

  • 29 Aug 2016 Phase-II clinical trials in Attention-deficit hyperactivity disorder (In adults) in USA (unspecified route)
  • 11 Jul 2016 Mazindol controlled release- NLS Pharma receives Orphan Drug status for Narcolepsy in USA
  • 09 Jun 2016 The US FDA approves IND application for Mazindol in Attention deficit hyperactivity disorder ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top